BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 17096741)

  • 1. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the treatment of patients with multiple myeloma.
    Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
    Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 7. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments for multiple myeloma.
    Richardson PG; Schlossman R; Hideshima T; Anderson KC
    Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New agents and approaches in the treatment of multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
    [No Abstract]   [Full Text] [Related]  

  • 19. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.